Nat Commun:肿瘤浸润性T细胞的T细胞受体库可预测癌症患者的预后

2021-07-04 xiaozeng MedSci原创

PD1(程序性死亡受体1)免疫检查点阻断(CPB)疗法被越来越多地用于治疗转移性实体瘤,患者的反应率为20-55%。

PD1(程序性死亡受体1)免疫检查点阻断(CPB)疗法被越来越多地用于治疗转移性实体瘤,患者的反应率为20-55%。该疗法也可作为局部晚期疾病的辅助或新辅助治疗策略。

然而鉴别对治疗获益的患者仍是一大难题,因此急需鉴定患者护理预测生物标志物来识别对CPB有更好反应的转移性癌症患者。此外,也需要相应的工具来筛选已通过手术治愈的复发风险较低的患者,以避免CPB相关治疗毒性的风险。

既往研究显示,T细胞的肿瘤浸润对于有效的抗癌免疫反应至关重要。因此,研究人员假设肿瘤浸润性T淋巴细胞(TIL/Tc)的T细胞受体(TCR)库可以指示这些细胞的功能状态并确定癌症不同阶段的病程。


在该研究中,研究人员发现,基线肿瘤浸润性T细胞TCR的多样性可用于预测各种癌症的预后,而T细胞浸润性转移性黑色素瘤的TCR克隆类型可预测PD1阻断免疫疗法的活性和功效。

TIL/Tc TCR可预测患者的总体生存率和对PD1 CPB的应答

总而言之,该研究结果揭示,在包括黑色素瘤在内的各种癌症中,TIL/Tc的多样性可以在没有PD1阻断的情况下预测患者的总体生存期(OS),而治疗前TIL/Tc的克隆类型可预测患者对抗PD1治疗的反应。


原始出处:

Valpione, S., Mundra, P.A., Galvani, E. et al. The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat Commun 12, 4098 (02 July 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1885280, encodeId=c63218852807c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 13:06:24 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969380, encodeId=26481969380fc, content=<a href='/topic/show?id=091d1002385e' target=_blank style='color:#2F92EE;'>#预测癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100238, encryptionId=091d1002385e, topicName=预测癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Mon Apr 11 18:06:24 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088055, encodeId=99582088055d9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jan 12 23:06:24 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289723, encodeId=911d1289e233d, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548138, encodeId=42c9154813859, content=<a href='/topic/show?id=0e021801ee9' target=_blank style='color:#2F92EE;'>#T细胞受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18017, encryptionId=0e021801ee9, topicName=T细胞受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df9b14008022, createdName=12498e67m32暂无昵称, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996441, encodeId=5dd6996441d1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Mon Jul 05 15:21:17 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2022-05-29 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1885280, encodeId=c63218852807c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 13:06:24 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969380, encodeId=26481969380fc, content=<a href='/topic/show?id=091d1002385e' target=_blank style='color:#2F92EE;'>#预测癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100238, encryptionId=091d1002385e, topicName=预测癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Mon Apr 11 18:06:24 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088055, encodeId=99582088055d9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jan 12 23:06:24 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289723, encodeId=911d1289e233d, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548138, encodeId=42c9154813859, content=<a href='/topic/show?id=0e021801ee9' target=_blank style='color:#2F92EE;'>#T细胞受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18017, encryptionId=0e021801ee9, topicName=T细胞受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df9b14008022, createdName=12498e67m32暂无昵称, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996441, encodeId=5dd6996441d1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Mon Jul 05 15:21:17 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1885280, encodeId=c63218852807c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 13:06:24 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969380, encodeId=26481969380fc, content=<a href='/topic/show?id=091d1002385e' target=_blank style='color:#2F92EE;'>#预测癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100238, encryptionId=091d1002385e, topicName=预测癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Mon Apr 11 18:06:24 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088055, encodeId=99582088055d9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jan 12 23:06:24 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289723, encodeId=911d1289e233d, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548138, encodeId=42c9154813859, content=<a href='/topic/show?id=0e021801ee9' target=_blank style='color:#2F92EE;'>#T细胞受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18017, encryptionId=0e021801ee9, topicName=T细胞受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df9b14008022, createdName=12498e67m32暂无昵称, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996441, encodeId=5dd6996441d1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Mon Jul 05 15:21:17 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2022-01-12 liuli5079
  4. [GetPortalCommentsPageByObjectIdResponse(id=1885280, encodeId=c63218852807c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 13:06:24 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969380, encodeId=26481969380fc, content=<a href='/topic/show?id=091d1002385e' target=_blank style='color:#2F92EE;'>#预测癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100238, encryptionId=091d1002385e, topicName=预测癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Mon Apr 11 18:06:24 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088055, encodeId=99582088055d9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jan 12 23:06:24 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289723, encodeId=911d1289e233d, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548138, encodeId=42c9154813859, content=<a href='/topic/show?id=0e021801ee9' target=_blank style='color:#2F92EE;'>#T细胞受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18017, encryptionId=0e021801ee9, topicName=T细胞受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df9b14008022, createdName=12498e67m32暂无昵称, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996441, encodeId=5dd6996441d1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Mon Jul 05 15:21:17 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1885280, encodeId=c63218852807c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 13:06:24 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969380, encodeId=26481969380fc, content=<a href='/topic/show?id=091d1002385e' target=_blank style='color:#2F92EE;'>#预测癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100238, encryptionId=091d1002385e, topicName=预测癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Mon Apr 11 18:06:24 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088055, encodeId=99582088055d9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jan 12 23:06:24 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289723, encodeId=911d1289e233d, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548138, encodeId=42c9154813859, content=<a href='/topic/show?id=0e021801ee9' target=_blank style='color:#2F92EE;'>#T细胞受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18017, encryptionId=0e021801ee9, topicName=T细胞受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df9b14008022, createdName=12498e67m32暂无昵称, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996441, encodeId=5dd6996441d1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Mon Jul 05 15:21:17 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1885280, encodeId=c63218852807c, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 29 13:06:24 CST 2022, time=2022-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969380, encodeId=26481969380fc, content=<a href='/topic/show?id=091d1002385e' target=_blank style='color:#2F92EE;'>#预测癌症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100238, encryptionId=091d1002385e, topicName=预测癌症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f9279, createdName=slcumt, createdTime=Mon Apr 11 18:06:24 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088055, encodeId=99582088055d9, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Jan 12 23:06:24 CST 2022, time=2022-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289723, encodeId=911d1289e233d, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548138, encodeId=42c9154813859, content=<a href='/topic/show?id=0e021801ee9' target=_blank style='color:#2F92EE;'>#T细胞受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18017, encryptionId=0e021801ee9, topicName=T细胞受体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df9b14008022, createdName=12498e67m32暂无昵称, createdTime=Tue Jul 06 14:06:24 CST 2021, time=2021-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996441, encodeId=5dd6996441d1, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Mon Jul 05 15:21:17 CST 2021, time=2021-07-05, status=1, ipAttribution=)]
    2021-07-05 1e1ad8bdm04(暂无匿称)

    学习

    0

相关资讯

Nat Commun:肠道微生物代谢物短链脂肪酸改善癌症的过继免疫疗法

肠道微生物群目前已被证实能够直接影响特定癌症免疫疗法的疗效。

2021年上半年盘点:NMPA批准了哪些癌症免疫疗法?

肿瘤免疫治疗作为继手术、放化疗、靶向药之后新一代的癌症治疗技术,从进入临床开始,就已经改变了很多癌症治疗的方式,为患者带来了新的治疗希望。

ESC Heart Failure:心力衰竭患者患癌风险更高!

近年来,随着我国生活水平逐渐提高以及人口老龄化到来,高血压、冠心病、糖尿病、老年瓣膜病等心血管疾病患病率也在逐年增长,而心力衰竭作为各种心血管病后期综合症,已成为社会广泛关注的焦点问题。

BMJ子刊:较高强度的运动或抵消睡眠不足带来的健康危害

轻度运动-睡眠不佳组合的参与者具有较高的全因、总心血管疾病、冠心病和肺癌的死亡风险。

Br J Cancer:长期癌症幸存者的益处发现BF和创伤后成长PTG评估

癌症作为一种危及生命的疾病,被认为是一种创伤性事件。

Ecancermedicalscience :阿司匹林可将癌症患者的死亡风险降低 20%

患有多种癌症的患者将阿司匹林作为治疗的一部分,可以帮助将他们的死亡风险降低 20%。